These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 27569671)

  • 41. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation.
    Yanagisawa D; Abe K; Amano H; Komatsuda S; Honda T; Manabe D; Yamamoto H; Kozuma K; Kodashima S; Asaoka Y; Yamamoto T; Tanaka A
    PLoS One; 2021; 16(11):e0260585. PubMed ID: 34843582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Target-specific oral anticoagulants and the hospitalist.
    Deitelzweig S; Amin A
    Hosp Pract (1995); 2015; 43(1):1-12. PubMed ID: 25559350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies.
    Villines TC; Peacock WF
    Am J Med; 2016 Nov; 129(11S):S41-S46. PubMed ID: 27569672
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Zirlik A; Bode C
    J Thromb Thrombolysis; 2017 Apr; 43(3):365-379. PubMed ID: 27896543
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-vitamin K antagonist oral anticoagulants (NOACs): clinical evidence and therapeutic considerations.
    Saraf K; Morris PD; Garg P; Sheridan P; Storey R
    Postgrad Med J; 2014 Sep; 90(1067):520-8. PubMed ID: 25085900
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 48. Security profile of direct anticoagulants. Preferred use in atrial fibrillation.
    Roldán Rabadán I; Alonso de Leciñana M; Barba Martín R; Páramo Fernández JA;
    Clin Investig Arterioscler; 2019; 31(6):263-270. PubMed ID: 31213323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
    Riva N; Lip GY
    Pol Arch Med Wewn; 2012; 122(1-2):45-53. PubMed ID: 22353706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
    Hsu JC; Hsieh CY; Yang YH; Lu CY
    PLoS One; 2015; 10(4):e0124806. PubMed ID: 25897861
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of Web-based education resources informing patients about stroke prevention in atrial fibrillation.
    Pandya E; Bajorek BV
    J Clin Pharm Ther; 2016 Dec; 41(6):667-676. PubMed ID: 27704588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience.
    Eikelboom J; Merli G
    Am J Med; 2016 Nov; 129(11S):S33-S40. PubMed ID: 27586367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
    Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
    Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Blumenstock G; Zuern CS; Ziemann U; Poli S
    Stroke; 2017 Sep; 48(9):2457-2463. PubMed ID: 28775134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
    Piccini JP; Lopes RD; Mahaffey KW
    Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
    Ritzenthaler T; Derex L; Davenas C; Bnouhanna W; Farghali A; Mechtouff L; Cho TH; Nighoghossian N
    Rev Neurol (Paris); 2015 Sep; 171(8-9):613-5. PubMed ID: 25857461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.